Skip to content
PeptideAI
Approved drugcardiovascular

Nesiritide

Recombinant human BNP given as an IV drip to drop filling pressures and relieve breathlessness in acute decompensated heart failure - effective on haemodynamics but not on outcomes.

Also known as Natrecor, recombinant human BNP, hBNP, B-type natriuretic peptide, Natrecor

Approved drug — Licensed by a major regulator for human use, with phase-3 trial data behind it.

FDA-approved in 2001 on the VMAC trial, which showed a genuine fall in pulmonary capillary wedge pressure and modest dyspnoea improvement. The 7,141-patient ASCEND-HF trial in 2011 then showed no reduction in death or rehospitalisation and only a marginal, non-significant dyspnoea benefit, with more hypotension. The manufacturer discontinued it in 2018; it is an honest example of a haemodynamically active peptide that failed on outcomes.

How it works

Nesiritide is a sequence-identical recombinant copy of the 32-amino-acid B-type natriuretic peptide the failing ventricle secretes in response to wall stress. It binds the particulate guanylyl cyclase receptor NPR-A on vascular smooth muscle, endothelium and renal tubular cells, raising cGMP and producing balanced venous and arterial dilatation with a fall in pulmonary capillary wedge pressure. It also suppresses renin, aldosterone and endothelin and promotes natriuresis, though the diuretic effect proved much weaker in practice than the haemodynamic one. Elimination is via NPR-C receptor internalisation, neutral endopeptidase degradation and renal filtration.

Targets: Natriuretic peptide receptor A (NPR-A / guanylyl cyclase A), cGMP pathway, Renin-angiotensin-aldosterone axis

Dosing

ProtocolDoseFrequencyRoute
Acute decompensated heart failure (label protocol)Given on admission for dyspnoea at rest or with minimal activity.—single bolus then continuous infusionintravenous
  • · 2 mcg/kg IV bolus followed by 0.01 mcg/kg/min infusion, typically for 24-48 hours. Weight-based, so no fixed microgram dose applies. Many centres skipped the bolus to reduce hypotension. Doses above 0.03 mcg/kg/min are not recommended.

Titration

Largely fixed-rate. If symptomatic hypotension develops the infusion is stopped or restarted at 30 percent lower with no bolus once blood pressure recovers.

Cycling

A short inpatient infusion, usually 24 to 48 hours. Serial or outpatient infusion protocols were studied and did not show benefit.

Work out your exact syringe units →

Pharmacology

Half-life
Initial phase about 2 minutes with a terminal half-life around 18 minutes; haemodynamic effects outlast the plasma level.
Onset
Wedge pressure falls within 15 minutes of the bolus; roughly 60 percent of the peak effect is present by 15 minutes.
Routes
intravenous
Molecule
Recombinant 32-amino-acid natriuretic peptide with a 17-residue disulfide ring
Sequence length
32 amino acids
Molecular weight
3464.05 Da

Handling

Diluent
Preservative-free 5% dextrose or 0.9% saline
Typical mix
5 mL
Vial sizes
1.5 mg
Lyophilised
Store vials at controlled room temperature 20-25 C or refrigerated 2-8 C.
Reconstituted
Use within 24 hours; the diluted bag is stable at room temperature for that period.

Mixing

The 1.5 mg vial is reconstituted with 5 mL from a prepared 250 mL infusion bag, then the contents are returned to the bag to give 6 mcg/mL. Rock the vial gently - do not shake. No bacteriostatic diluents.

Side effects

  • very commonHypotension— The defining side effect; often prolonged because the haemodynamic effect outlasts the short plasma half-life.
  • commonWorsening renal function— A meta-analysis signal that dogged the drug, though ASCEND-HF did not confirm a hard renal harm.
  • commonHeadache
  • commonNausea, dizziness
  • uncommonVentricular arrhythmia

Do not use if

  • Cardiogenic shock or systolic blood pressure below 90 mmHg - nesiritide will make it worse.
  • Conditions where cardiac output depends on preload or venous return, such as significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis or pericardial tamponade.
  • Known hypersensitivity to nesiritide or its components.
  • Use through a heparin-coated catheter, which binds the drug.

Combining it

  • cautionACE inhibitors — Additive hypotension; the combination raises the rate of symptomatic low blood pressure.
  • cautionloop diuretics — Commonly co-administered but the combination amplifies hypotension and renal hypoperfusion.
  • redundantsacubitril-valsartan — Both amplify natriuretic peptide signalling; combining them is pharmacologically duplicative and adds hypotension risk.

What to monitor

  • · Continuous or frequent blood pressure measurement, at minimum every 15 minutes after the bolus.
  • · Serum creatinine and electrolytes daily.
  • · Urine output and daily weights.
  • · Symptom score for dyspnoea, which is the endpoint the drug actually moves.

Legal status

Was an FDA-approved prescription drug; discontinued commercially in 2018 and no longer marketed in the US.

References

  • Natrecor (nesiritide) FDA prescribing information (label)
  • VMAC Investigators 2002, intravenous nesiritide versus nitroglycerin in decompensated heart failure (trial)
  • O'Connor et al. 2011, ASCEND-HF, effect of nesiritide in acute decompensated heart failure (trial)

Mechanism in depth

Nesiritide is human BNP-32 made in a fermenter, so the mechanism is simply the endogenous system pushed harder. It binds NPR-A (also called particulate guanylyl cyclase A), a single-pass receptor whose intracellular domain is itself a guanylyl cyclase. Ligand binding raises intracellular cGMP, which activates protein kinase G, which phosphorylates myosin light chain phosphatase and lowers intracellular calcium in vascular smooth muscle. The result is balanced venodilation and arterial dilation: preload falls, which is what drops pulmonary capillary wedge pressure and relieves orthopnoea, and afterload falls modestly. In the kidney, cGMP dilates the afferent arteriole and constricts the efferent, raises filtration fraction and inhibits sodium reabsorption in the inner medullary collecting duct. There is also direct suppression of renin and aldosterone and of sympathetic outflow. On paper this is the perfect heart failure drug. The reason it failed is instructive: acute decompensated heart failure is not primarily a vasoconstriction problem, the haemodynamic improvement does not translate into fewer deaths or readmissions, tachyphylaxis develops during prolonged infusion, and the drug's own hypotension limits how hard it can be pushed in exactly the patients with the most congestion. The effect on blood pressure outlasts the plasma level, which is why hypotension after stopping the infusion can persist for a couple of hours.

What usually goes wrong

Hypotension, and specifically hypotension that continues after the infusion is stopped because the haemodynamic effect outlasts the plasma level. Beyond that, the real failure was conceptual: a drug that improves the numbers on a Swan-Ganz catheter and the patient's sense of breathlessness at three hours, but does not change whether they come back or die. Nesiritide is the cleanest cautionary example in this class of a peptide that does exactly what it was designed to do at the receptor and still fails at the endpoint that matters. The manufacturer discontinued it in 2018.

Bloodwork worth running

MarkerWhenWhy it matters
Systolic blood pressure (not a lab, but the governing number)Continuously or every 15 minutes during titration.Symptomatic hypotension is the dose-limiting effect and occurred more often than with nitroglycerin in VMAC and more often than placebo in ASCEND-HF.Act if: Systolic below 100 mmHg at baseline is a reason not to start. A fall below 90 mmHg on infusion means stop; expect a further one to two hours before pressure recovers.
Serum creatinine and eGFRBaseline and daily during infusion.The pooled analyses that damaged nesiritide's reputation reported an increased risk of worsening renal function. ASCEND-HF did not confirm renal harm, but creatinine remains the number that decides whether an infusion continues.Act if: A rise of 0.3 mg/dL or more, particularly with falling blood pressure, should stop the infusion rather than prompt more diuretic.
BNP immunoassayIf a natriuretic peptide level is needed during or within hours of an infusion, order NT-proBNP, not BNP.This is the trap. Nesiritide is BNP, so BNP immunoassays cannot distinguish drug from endogenous hormone and the result becomes uninterpretable during and shortly after infusion. NT-proBNP is not affected because it is a different fragment.Act if: Do not act on a high BNP drawn during a nesiritide infusion; it is measuring the drug.
Serum potassium and sodiumDaily.Natriuresis and concurrent loop diuretics move both, and hyponatraemia in acute heart failure is a prognostic marker in its own right.Act if: Potassium below 3.5 mmol/L needs replacement before further diuresis.

Pharmacokinetics

Bioavailability
100%
Time to steady state
0.06 days
Crosses blood-brain barrier
no
Metabolism
Neprilysin cleavage and NPR-C-mediated internalisation. Clinically this matters because a patient on sacubitril/valsartan has neprilysin inhibited, which changes endogenous and exogenous natriuretic peptide handling.
Elimination
Receptor-mediated clearance and enzymatic degradation dominate; renal filtration is minor.

Receptor targets

  • NPR-A / particulate guanylyl cyclase A (NPR1)

    The therapeutic receptor. Raises cGMP, producing venous and arterial dilation, natriuresis, and suppression of renin, aldosterone and sympathetic tone.

  • NPR-C (natriuretic peptide clearance receptor)

    No signalling output of consequence; binding leads to internalisation and degradation. This is a major clearance route and a reason effect plateaus.

Trials

  • VMAC (Vasodilation in the Management of Acute Congestive Heart Failure) Phase 3 · n=489 · 0.15 weeks · 2002

    Change in pulmonary capillary wedge pressure at 3 hours in catheterised patients and patient-reported dyspnoea at 3 hours in all patients. Nesiritide dropped PCWP by a mean of 5.8 mmHg and modestly improved dyspnoea versus placebo. This was the approval trial.

  • ASCEND-HF Phase 3 · n=7141 · 4.3 weeks · 2011

    Co-primary of dyspnoea change at 6 and 24 hours and the composite of 30-day heart failure rehospitalisation or death. Dyspnoea improvement was nominally better (44.5 versus 42.1 percent at 6 hours) but missed the prespecified significance threshold; rehospitalisation or death was 9.4 versus 10.1 percent, not significant. More hypotension. This trial ended the drug.

What to expect, and when

Haemodynamic effect begins within 15 minutes of the bolus and about 60 percent of the peak blood pressure effect is present within 15 minutes. Full effect on wedge pressure within 3 hours. After stopping, the plasma level falls with an 18-minute terminal half-life but blood pressure effects persist for up to two hours.

Stacking and comparisons

Nesiritide was used alongside loop diuretics, and the interaction is additive hypotension plus additive renal hypoperfusion. Adding it to a nitrate is redundant and hypotensive; VMAC compared the two rather than combining them. ACE inhibitors, ARBs and especially sacubitril/valsartan potentiate the effect, and neprilysin inhibition changes natriuretic peptide handling directly. Phosphodiesterase-5 inhibitors act on the same cGMP pathway downstream and combine into serious hypotension.

Against nitroglycerin, the comparator in VMAC: nesiritide dropped wedge pressure more at 3 hours and needed less dose titration, but nitroglycerin costs almost nothing and does not carry a mortality controversy. Against carperitide, the Japanese ANP analogue in the same class: same receptor, same haemodynamics, same absence of randomised outcome benefit, but carperitide remains in routine Japanese practice while nesiritide was withdrawn. Against cenderitide, the designer chimera built specifically to keep the renal effects while losing the hypotension: cenderitide never got far enough to test the hypothesis.

Rough cost

Discontinued in 2018; no current price. When marketed it was a notably expensive inpatient infusion relative to nitroglycerin, which was part of the health-economics argument against it.

Genuinely uncertain

  • Volume of distribution and clearance figures for nesiritide (commonly quoted as about 0.19 L/kg and 9.2 mL/min/kg from the withdrawn Natrecor label) could not be re-verified against a live label in this session, so those fields are left null.
  • The claim that nesiritide interferes with BNP immunoassays while leaving NT-proBNP unaffected is standard laboratory teaching but I did not resolve a primary citation for it here.
  • Whether tachyphylaxis to nesiritide is receptor desensitisation, counter-regulatory neurohormonal activation, or both is not settled.

Papers